Parabilis Medicines, Inc.

PBLS is in a constructive post-IPO trend, holding above its 200-day moving average and trading in the upper half of its 52-week range. The setup favors a stock still working through price discovery, with the recent base built well above the yearly low and below the high.

Street coverage is newly positive, with Leerink, Guggenheim, and Evercore all starting the name at Outperform or Buy. The target cluster is tightly grouped at $40, above the current share price, which points to upside bias rather than a split view.

No earnings beat/miss history is available yet, and next-year EPS is still expected to be negative at -1.9 versus -1.77 TTM. Shareholders should watch for clinical progress, cash burn, and whether management can narrow losses as the pipeline advances.

No notable insider buying or selling in recent quarters. With no reported transactions, the tape does not currently signal a meaningful discretionary insider view.

Profitability remains deeply negative, with EPS at -1.77 TTM and no reported margin profile yet. Cash burn is the key watchpoint: operating cash flow was -$123.7 million in 2025, while cash and equivalents stood at $27.7 million.

As a clinical-stage biotech, PBLS is valued on pipeline execution rather than current earnings power. The stock trades at a negative P/E and sits below the $40 analyst target cluster, leaving valuation tied to trial and platform milestones.